[
  {
    "ts": null,
    "headline": "Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "summary": "Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=b18939a63ec30201d183def73b6a7efabc4265ce2314ecd19dcbfc8dcc3aea8a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743614280,
      "headline": "Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "id": 133687398,
      "image": "",
      "related": "RVTY",
      "source": "MarketWatch",
      "summary": "Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=b18939a63ec30201d183def73b6a7efabc4265ce2314ecd19dcbfc8dcc3aea8a"
    }
  },
  {
    "ts": null,
    "headline": "Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test",
    "summary": "WALTHAM, Mass., April 02, 2025--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-",
    "url": "https://finnhub.io/api/news?id=2136e3f1fd986755080285f3b8ff60730fc4f8584113cdf2be5d26609aae0cc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743595200,
      "headline": "Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test",
      "id": 133666277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., April 02, 2025--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster high-",
      "url": "https://finnhub.io/api/news?id=2136e3f1fd986755080285f3b8ff60730fc4f8584113cdf2be5d26609aae0cc4"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
    "summary": "RVTY's strong product portfolio raises optimism about the stock.",
    "url": "https://finnhub.io/api/news?id=56e31acecc77c0c1e673fdc5fbc8c268c25be6aa19400e185e1b2e80fb1986b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743594420,
      "headline": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
      "id": 133670194,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "RVTY's strong product portfolio raises optimism about the stock.",
      "url": "https://finnhub.io/api/news?id=56e31acecc77c0c1e673fdc5fbc8c268c25be6aa19400e185e1b2e80fb1986b2"
    }
  }
]